Silo Pharma Files 8-K/A: Administrative Update to Prior Report
Ticker: SILO · Form: 8-K/A · Filed: Jan 11, 2024 · CIK: 1514183
| Field | Detail |
|---|---|
| Company | Silo Pharma, Inc. (SILO) |
| Form Type | 8-K/A |
| Filed Date | Jan 11, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $1 million, $487,016 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: amendment, corporate-governance, compliance
TL;DR
**Silo Pharma's 8-K/A is just an administrative fix, no new news.**
AI Summary
Silo Pharma, Inc. filed an 8-K/A on January 11, 2024, amending a previous report from January 9, 2024. This filing is an administrative update, primarily correcting or clarifying information in the original 8-K. For investors, this filing indicates that the company is diligently maintaining its public disclosures, but it doesn't reveal new financial or operational news that would directly impact the stock price.
Why It Matters
This filing is an administrative amendment, meaning it corrects or clarifies details in a previous report, rather than announcing new material events. It shows the company is keeping its records accurate, which is good for transparency, but it doesn't provide new information that would change an investor's outlook.
Risk Assessment
Risk Level: low — This 8-K/A is an amendment to a previous filing, typically for minor corrections or clarifications, and does not introduce new financial or operational risks.
Analyst Insight
A smart investor would note this filing as a routine administrative update and not expect any immediate stock price movement. It's a good sign of compliance but doesn't offer new fundamental information to act upon.
Key Players & Entities
- Silo Pharma, Inc. (company) — the registrant filing the 8-K/A
- January 9, 2024 (date) — date of the earliest event reported in the original 8-K
- January 11, 2024 (date) — date the 8-K/A was filed
- 677 N. Washington Boulevard Sarasota, FL 34236 (address) — Silo Pharma's principal executive offices
- (718) 400-9031 (phone_number) — Silo Pharma's business telephone number
FAQ
What is the purpose of an 8-K/A filing for Silo Pharma, Inc.?
An 8-K/A filing, like the one from Silo Pharma, Inc. on January 11, 2024, is an amendment to a previously filed 8-K. It is used to correct, update, or clarify information that was included in the original report, as indicated by the 'AMENDED CURRENT REPORT' notation in the filing.
When was the earliest event reported in the original 8-K that this 8-K/A amends?
The earliest event reported in the original 8-K, which this 8-K/A amends, occurred on January 9, 2024, as stated under 'Date of Report (Date of earliest event reported): January 9, 2024'.
What is Silo Pharma, Inc.'s business address and phone number according to this filing?
Silo Pharma, Inc.'s business address is 677 N. Washington Boulevard, Sarasota, FL 34236, and their telephone number is (718) 400-9031, as listed in the 'BUSINESS ADDRESS' and 'BUSINESS PHONE' sections of the filing.
What is Silo Pharma, Inc.'s Central Index Key (CIK) and SEC File Number?
Silo Pharma, Inc.'s Central Index Key (CIK) is 0001514183 and their SEC File Number is 001-41512, as detailed in the 'COMPANY DATA' and 'FILING VALUES' sections of the filing.
Has Silo Pharma, Inc. operated under different names in the past?
Yes, Silo Pharma, Inc. has operated under several former names, including Uppercut Brands, Inc. (changed August 8, 2019), Point Capital, Inc. (changed January 30, 2013), and Gold Swap Inc (changed March 1, 2011), as listed in the 'FORMER COMPANY' sections of the filing.
Filing Stats: 493 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-01-11 12:15:59
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SILO The Nasdaq Stock Mar
- $1 million — ogram authorizing the purchase of up to $1 million of the Company's common stock until Mar
- $487,016 — of its common stock for a total cost of $487,016 pursuant to its Stock Repurchase Progra
Filing Documents
- ea191517-8k_silo.htm (8-K/A) — 25KB
- 0001213900-24-002881.txt ( ) — 193KB
- silo-20240109.xsd (EX-101.SCH) — 3KB
- silo-20240109_lab.xml (EX-101.LAB) — 33KB
- silo-20240109_pre.xml (EX-101.PRE) — 22KB
- ea191517-8k_silo_htm.xml (XML) — 3KB
01 – Other Events
Item 8.01 – Other Events On January 9, 2024, the Board of Directors of the Company approved an extension of the previously announced Stock Repurchase Program authorizing the purchase of up to $1 million of the Company's common stock until March 31, 2024. As of December 31, 2023, the Company had repurchased an aggregate of 264,196 shares of its common stock for a total cost of $487,016 pursuant to its Stock Repurchase Program.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILO PHARMA, INC. Date: January 11, 2024 By: /s/ Eric Weisblum Eric Weisblum Chief Executive Officer